Personalisierte Therapie des Mammakarzinoms

Für Patientinnen mit Mammakarzinom gibt es die Möglichkeit einer individualisierten bzw. personalisierten Therapie. Dies gilt sowohl für das frühe Mammakarzinom als auch in der Situation der Metastasierung. Basis hierfür sind neue Testverfahren, die zusätzliche Erkenntnisse über das biologische Verhalten liefern und damit den Tumor weiter charakterisieren.

• Literatur

• 1 Gianni L. Pienkowski T. Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32
• 2 Schneeweiss A. Chia S. Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278-2284
• 3 Baselga J. Cortés J. Kim SB. et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 2012; 366: 109-119
• 4 Swain SM. Baselga J. Kim SB. et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med 2015; 372: 724-734
• 5 Verma S. Miles D. Gianni L. et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012; 367: 1783-1791
• 6 Krop IE. Lin NU. Blackwell K. et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2015; 26: 113-119
• 7 Sutherland RL. Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 2009; 11 DOI: 10.1186/bcr2454.
• 8 Finn RS. Dering J. Conklin D. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11 DOI: 10.1186/bcr2419.
• 9 Finn RS. Martin M. Rugo HS. et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC), 2016 ASCO Annual Meeting, Abstract 507.